JP2015527875A5 - - Google Patents

Download PDF

Info

Publication number
JP2015527875A5
JP2015527875A5 JP2015516469A JP2015516469A JP2015527875A5 JP 2015527875 A5 JP2015527875 A5 JP 2015527875A5 JP 2015516469 A JP2015516469 A JP 2015516469A JP 2015516469 A JP2015516469 A JP 2015516469A JP 2015527875 A5 JP2015527875 A5 JP 2015527875A5
Authority
JP
Japan
Prior art keywords
seq
nucleotide sequence
st6galnac3
c1orf114
hapln3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516469A
Other languages
English (en)
Japanese (ja)
Other versions
JP6242388B2 (ja
JP2015527875A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2013/050196 external-priority patent/WO2013185779A2/en
Publication of JP2015527875A publication Critical patent/JP2015527875A/ja
Publication of JP2015527875A5 publication Critical patent/JP2015527875A5/ja
Application granted granted Critical
Publication of JP6242388B2 publication Critical patent/JP6242388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516469A 2012-06-14 2013-06-14 前立腺ガンのバイオマーカー Active JP6242388B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270326 2012-06-14
DKPA201270326 2012-06-14
PCT/DK2013/050196 WO2013185779A2 (en) 2012-06-14 2013-06-14 Biomarkers for prostate cancer

Publications (3)

Publication Number Publication Date
JP2015527875A JP2015527875A (ja) 2015-09-24
JP2015527875A5 true JP2015527875A5 (enExample) 2016-07-07
JP6242388B2 JP6242388B2 (ja) 2017-12-06

Family

ID=48740787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516469A Active JP6242388B2 (ja) 2012-06-14 2013-06-14 前立腺ガンのバイオマーカー

Country Status (6)

Country Link
US (1) US10106854B2 (enExample)
EP (1) EP2861759B1 (enExample)
JP (1) JP6242388B2 (enExample)
AU (1) AU2013275761B2 (enExample)
CA (1) CA2876252A1 (enExample)
WO (1) WO2013185779A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971179B1 (en) 2013-03-14 2019-01-09 Mayo Foundation for Medical Education and Research Detecting neoplasm
EP3037545A1 (en) * 2014-12-23 2016-06-29 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin A DNA-methylation test for prostate cancer
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
JP6871926B2 (ja) 2015-08-31 2021-05-19 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ ａｎｄ Ｒｅｓｅａｒｃｈ 胃の新生物を検出すること
CN106480169B (zh) * 2015-09-01 2019-10-08 杨小丽 人aqp10和sox17基因甲基化位点的检测和应用
US10934592B2 (en) * 2017-02-28 2021-03-02 Mayo Foundation For Medical Education And Research Detecting prostate cancer
GB201816820D0 (en) 2018-10-16 2018-11-28 Univ York Diagnostic method
EP3880846B1 (en) 2018-11-13 2024-08-28 Bracco Imaging SPA Gene signatures for the prediction of prostate cancer recurrence
CN109468381B (zh) * 2018-11-19 2022-11-25 兰州市第一人民医院 用于宫颈癌筛查的甲基化位点及其检测引物
EP3999662A1 (en) * 2019-07-19 2022-05-25 Vilnius University Characterization of prostate cancer using dna methylation assay system
CN113122634B (zh) * 2020-01-14 2026-03-10 江苏鹍远生物科技股份有限公司 检测dna甲基化的试剂及用途
CA3172143A1 (en) * 2020-05-04 2021-11-11 David A. Ahlquist Detecting pancreatic neuroendocrine tumors
US20230212684A1 (en) * 2020-05-05 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Cell-free dna biomarkers and their use in diagnosis, monitoring response to therapy, and selection of therapy for prostate cancer
CN118685523B (zh) * 2024-08-26 2024-11-15 湖南宏雅基因技术有限公司 一种用于前列腺癌检测的生物标志物组合、引物探针组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6605432B1 (en) 1999-02-05 2003-08-12 Curators Of The University Of Missouri High-throughput methods for detecting DNA methylation
WO2002070742A1 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
US20100297067A1 (en) 2007-05-14 2010-11-25 The Johns Hopkins University Methylation markers for prostate cancer and methods of use
EP2329041A1 (en) 2008-08-05 2011-06-08 Veridex, LLC Prostate cancer methylation assay
ES2595410T3 (es) * 2009-01-07 2016-12-29 Myriad Genetics, Inc. Biomarcadores de cáncer
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011037936A2 (en) * 2009-09-24 2011-03-31 Oregon Health & Science University Detection of dna methylation of tal1, erg and/or cd40 to diagnose prostate cancer
WO2011044902A1 (en) 2009-10-13 2011-04-21 Aarhus Universitet Tff3 hypomethylation as a novel biomarker for prostate cancer
WO2011112845A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2012138609A2 (en) * 2011-04-04 2012-10-11 The Board Of Trustees Of The Leland Stanford Junior University Methylation biomarkers for diagnosis of prostate cancer

Similar Documents

Publication Publication Date Title
JP6721665B2 (ja) 目的遺伝子発現の線形結合を用いた細胞信号伝達経路活性の評価
Zhang et al. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling
US20200370127A1 (en) Biomarkers in Peripheral Blood Mononuclear Cells for Diagnosing or Detecting Lung Cancers
JP6246845B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
CN103733065B (zh) 用于癌症的分子诊断试验
Ura et al. Potential role of circulating microRNAs as early markers of preeclampsia
AU2016200494A1 (en) Molecular diagnostic test for cancer
JP2016536001A (ja) 肺がんのための分子診断試験
JP2015536667A (ja) 癌のための分子診断検査
JP2011500071A (ja) 遺伝子に基づくアルゴリズム的ガン予後及び患者の臨床結果
EP3044327A1 (en) Molecular diagnostic test for oesophageal cancer
CN101173313B (zh) 乳腺癌转移和预后分子分型基因群及其基因芯片制备和应用方法
US20240352530A1 (en) Circulating microrna panel for the early detection of breast cancer and methods thereof
EP3409794A1 (en) Circulating mirnas as early detection marker and prognostic marker
Azadeh et al. Decreased expression level of long non-coding RNA CCAT1, was observed in breast cancer tissue of an Isfahanian population (Iran)
CN113736879A (zh) 用于小细胞肺癌患者预后的系统及其应用
CN112063714A (zh) 一种与结直肠癌相关的miRNA及其应用
WO2014111561A1 (en) Serum mirna-142-3p as prognostic cancer marker
JP2020528733A (ja) 肝細胞癌（ｈｃｃ）または胆管癌（ｃｃａ）を有する被験者の生存転帰を予測する方法
CN113826166A (zh) 评估气道上皮细胞中的多信号传导途径活性评分以预测气道上皮异常和气道癌风险
US20240093306A1 (en) Micro rna liver cancer markers and uses thereof
JP2024507775A (ja) 乳がんの診断のためのバイオマーカー
JP7663987B2 (ja) 非小細胞肺癌のモニタリング方法およびキット
CN115094059B (zh) 生物标志物在制备辅助诊断癌症的试剂中的应用
JPWO2007088971A1 (ja) がん予後判定に利用できる遺伝子群